Diridavumab

Diridavumab
Monoclonal antibody
Type	?
Source	Human
Target	hemagglutinin
Identifiers
CAS Number	1393659-46-5
ATC code	None
ChemSpider	none
Chemical data
Formula	C₆₄₀₀H₉₉₃₄N₁₇₀₂O₁₉₉₆S₄₈
Molar mass	144.2 kDa

Diridavumab^[1] is a monoclonal antibody designed for the treatment of influenza A.^[2]

This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.

References

↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information 28 (2).
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Chimeric ("-toxaxi-")	Obiltoxaximab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.